Previous 10 | Next 10 |
2024-02-15 16:23:49 ET More on Corcept Therapeutics Corcept Therapeutics Q4 2023 Earnings Preview Corcept Therapeutics reports prelim Q4 rev above estimate Seeking Alpha’s Quant Rating on Corcept Therapeutics Historical earnings data for Corcept Therap...
MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the...
MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the...
Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...
MENLO PARK, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2023 financial results and provide a corporate update on February 15, 2024. The company will also host a conference call that day at 5...
MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the...
2024-01-22 08:26:07 ET Losers: Archer Daniels Midland Co. ADM -15% on leave amid accounting probe, trims FY 2023 earnings guidance . B. Riley Financial ( RILY ) -15% issues financial Statement . Bionomics Ltd. ( BNOX ) -11% provides a Review of 20...
2024-01-08 08:45:52 ET More on Corcept Therapeutics Analyzing Corcept's Strategic Shift In A Competitive Pharma Landscape Corcept Therapeutics Incorporated (CORT) Q3 2023 Earnings Call Transcript Canaccord Genuity sees Corcept sell-off as buying opportunity B...
MENLO PARK, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormo...
2024-01-07 02:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Corcept Therapeutics Incorporated Company Name:
CORT Stock Symbol:
NASDAQ Market:
Results from the CATALYST clinical trial were presented at the American Diabetes Association’s 84 th Scientific Sessions at a featured plenary session titled: “Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes” With 1,055 patients enro...
2024-06-12 10:00:07 ET Edward Nash from Canaccord Genuity issued a price target of $38.00 for CORT on 2024-06-12 07:45:00. The adjusted price target was set to $38.00. At the time of the announcement, CORT was trading at $32.79. The overall price target consensus is at $...
Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) traded at a new 52-week high today and are currently trading at $34.06. So far today, approximately 79,094 shares have been exchanged, as compared to an average 30-day volume of 1.09M shares. Corcept Therapeutics Incorporated discover...